🔎 Trials Near Me

Почетна › Srpastoćelijska bolest › Тексас › Houston

Kliničke studije za Srpastoćelijska bolest u gradu Houston, TX

12 studija za Srpastoćelijska bolest traži učesnike na lokacijama u gradu Houston i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.

Zvanični tekst studije (na engleskom)

Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Тражи се учесникФаза 3
  • Texas Childrens Cancer and Hematology Center, Houston
  • U of TX Health Science Ct, Houston
Узраст од 12 до 100 · Оба пола · Ажурирано 10. 11. 2026. · NCT06439082

Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

Тражи се учесникФаза 2
  • UT Physicians Comprehensive Adult Sickle Cell Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07224360

A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)

Тражи се учесникФаза 3
  • University of Texas Health Science Center at Houston, Houston
Узраст 12 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT07656415

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

Тражи се учесникФаза 1/2Здраве особе су добродошле
  • UT Health Science Center, Houston
Узраст од 12 до 55 · Оба пола · Ажурирано 27. 10. 2026. · NCT06546670

The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

Тражи се учесникФаза 3
  • Baylor College of Medicine- Site Number : 8400055, Houston
  • UT Physicians - Memorial Hermann- Site Number : 8400052, Houston
Узраст од 10 до 65 · Оба пола · Ажурирано 15. 10. 2026. · NCT06975865

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

Тражи се учесникФаза 3
  • Texas Children's Hospital_Houston, Houston
  • UT Health University of Texas, Houston
Узраст 2 и старији · Оба пола · Ажурирано 18. 9. 2026. · NCT06609226

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

Тражи се учесникФаза 3
  • UT Health University of Texas, Houston
Узраст 12 и старији · Оба пола · Ажурирано 17. 9. 2026. · NCT06612268

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

Тражи се учесникОпсервациона студија
  • Gulf States Hemophilia and Thrombophilia Center, Houston
  • Texas Children's Hemophilia & Thrombosis Center/Baylor College of Medicine, Houston
Сви узрасти · Оба пола · Ажурирано 17. 8. 2026. · NCT04398628

Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease

Тражи се учесникОпсервациона студија
  • Texas Children's Hopsital (NT-DMT), Houston
  • Texas Children's Hospital (MRD-HCT), Houston
Узраст од 3 до 20 · Оба пола · Ажурирано 4. 6. 2026. · NCT06941389

Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

Тражи се учесникФаза 3
  • Site # 8400004, Houston
Узраст од 2 до 17 · Оба пола · Ажурирано 15. 4. 2026. · NCT07247188

Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial

Тражи се учесникФаза 2
  • Baylor College of Medicine, Houston
Узраст од 15 до 40 · Оба пола · Ажурирано 13. 3. 2026. · NCT06260891

Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease

Тражи се учесникОпсервациона студија
  • University of Texas at Houston, Houston
Узраст 18 и старији · Оба пола · Ажурирано 22. 6. 2025. · NCT06385886

Studije za Srpastoćelijska bolest u drugim gradovima

Ostale studije u gradu Houston

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.